Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 13/20 | 0.55 |
| ▸ | KDR | P35968 | 8/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.55 |
| ▸ | EGFR | P00533 | 4/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.55 |
| ▸ | FLT3 | P36888 | 3/20 | 0.55 |
| ▸ | FLT4 | P35916 | 3/20 | 0.55 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 2/20 | 0.55 |
| ▸ | LYN | P07948 | 2/20 | 0.55 |
| ▸ | RET | P07949 | 2/20 | 0.55 |
| ▸ | HCK | P08631 | 2/20 | 0.55 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.55 |
| ▸ | MST1R | Q04912 | 2/20 | 0.55 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.55 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.55 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.55 |
| ▸ | FLT1 | P17948 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028143 | 0.89 | AURKA (0.56) | AURKAKDRAURKBPDGFRBEGFR | |
| SCHEMBL6027595 | 0.88 | AURKA (0.71) | AURKAKDRAURKBPDGFRBEGFR | |
| SCHEMBL6090156 | 0.88 | AURKA (0.71) | AURKAKDRAURKBPDGFRBEGFR | |
| SCHEMBL6027847 | 0.87 | AURKA (0.57) | AURKAKDRAURKBPDGFRBEGFR | |
| SCHEMBL6026358 | 0.86 | PDGFRB (0.53) | AURKAKDRAURKBPDGFRBEGFR | |
| SCHEMBL6028149 | 0.86 | AURKA (0.53) | AURKAKDRAURKBPDGFRBEGFR | |
| SCHEMBL6028218 | 0.85 | AURKA (0.54) | AURKAKDRAURKBPDGFRBEGFR | |
| SCHEMBL6027522 | 0.85 | AURKA (0.57) | AURKAKDRAURKBPDGFRBEGFR | |
| SCHEMBL6031396 | 0.84 | AURKA (0.55) | AURKAKDRAURKBPDGFRBEGFR | |
| SCHEMBL6029185 | 0.84 | AURKA (0.59) | AURKAKDRAURKBPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | claimed |
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| US-20060089353-A1 | Indole derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1644361-A1 | CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS | Astrazeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004113324-A1 | CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089353-A1 | Indole derivative compounds and drugs containing the compounds as the active ingredient | PTGIS, IDO1, IDO2 | AURKA 1042/4885KDR 694/4885AURKB 418/4885 |
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | AURKA, AURKC, AURKB | AURKA 1/4885KDR 1914/4885AURKB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.